Loading...

Siegfried Holding AG

0QQO.LLSE
Healthcare
Medical - Pharmaceuticals
£86.40
£-0.20(-0.23%)

Siegfried Holding AG (0QQO.L) Financial Performance & Income Statement Overview

Review Siegfried Holding AG (0QQO.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
1.82%
1.82%
Operating Income Growth
15.80%
15.80%
Net Income Growth
41.93%
41.93%
Operating Cash Flow Growth
-19.09%
19.09%
Operating Margin
15.39%
15.39%
Gross Margin
25.42%
25.42%
Net Profit Margin
12.36%
12.36%
ROE
17.33%
17.33%
ROIC
12.25%
12.25%

Siegfried Holding AG (0QQO.L) Income Statement & Financial Overview

Analyze Siegfried Holding AG’s 0QQO.L earnings with segmented quarterly and yearly financial statement figures.

MetricQ4 2024Q2 2024Q4 2023Q2 2023
Revenue$674.67M$619.90M$664.44M$607.05M
Cost of Revenue$505.13M$460.38M$491.72M$459.37M
Gross Profit$169.53M$159.52M$172.72M$147.69M
Gross Profit Ratio$0.25$0.26$0.26$0.24
R&D Expenses$19.40M$21.72M$21.57M$22.93M
SG&A Expenses$47.71M$50.65M$59.42M$49.40M
Operating Expenses$58.13M$71.66M$80.99M$72.33M
Total Costs & Expenses$563.27M$532.05M$572.71M$531.70M
Interest Income-$366000.00$2.53M$325000.00$245000.00
Interest Expense$3.71M$4.79M$5.19M$4.30M
Depreciation & Amortization$41.88M$42.84M$42.82M$38.54M
EBITDA$158.79M$130.70M$123.53M$120.53M
EBITDA Ratio$0.24$0.21$0.20$0.19
Operating Income$111.40M$87.86M$91.73M$75.35M
Operating Income Ratio$0.17$0.14$0.14$0.12
Other Income/Expenses (Net)-$5.14M$2.15M-$16.21M-$496000.00
Income Before Tax$106.27M$90.003M$75.52M$74.86M
Income Before Tax Ratio$0.16$0.15$0.11$0.12
Income Tax Expense$17.65M$18.73M$18.03M$19.65M
Net Income$88.68M$71.38M$57.56M$55.22M
Net Income Ratio$0.13$0.12$0.09$0.09
EPS$20.50$16.64$13.56$13.00
Diluted EPS$20.30$16.58$13.23$12.99
Weighted Avg Shares Outstanding$43.09M$42.89M$4.24M$4.25M
Weighted Avg Shares Outstanding (Diluted)$43.41M$43.05M$4.35M$4.25M

Over the past four quarters, Siegfried Holding AG demonstrated steady revenue growth, increasing from $607.05M in Q2 2023 to $674.67M in Q4 2024. Operating income reached $111.40M in Q4 2024, maintaining a consistent 17% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $158.79M, reflecting operational efficiency. Net income rose to $88.68M, with EPS at $20.50. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;